At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding of the current state of the biosimilar market as well as on future challenges of the development and regulation of biosimilars.
Biosimilars, which are biological products that demonstrate no clinically meaningful differences to an approved biological product, are currently approved in several areas of the world, and the biosimilars development pipeline is relatively large.
